Clinical and Microbiological Evaluation of Topical Dutasteride as a Potential New Therapy of Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)

Acne vulgaris (AV) is one of the most prevalent dermatological conditions worldwide, affecting approximately 85% of adolescents and young adults between the ages of 12 and 24 years .While acne is often self-limiting, it can have profound psychosocial implications as individuals with acne are more likely to experience emotional distress, lower self-esteem and anxiety disorders .
Acne Vulgaris is a chronic inflammatory skin condition affecting the pilosebaceous units that leads to the development of different skin lesions such as comedones, papules, pustules, nodules and cystic lesions .

Start Date01 Apr 2026

Sponsor / Collaborator

Assiut University

NCT07420517

/ Not yet recruitingPhase 2IIT

A Phase II Prospective Single-arm Study of Dutasteride in Patients With Low-grade Non-muscle Invasive Bladder Cancer

Low-grade non-muscle-invasive bladder cancer often comes back after treatment, requiring repeated surgeries, especially in older patients. These recurrences can cause complications, reduce quality of life, and increase healthcare costs. Currently, there is no well-tolerated preventive treatment routinely used for this low-risk disease.
This study will evaluate whether dutasteride, an oral medication that blocks androgen activity, can reduce the risk of bladder cancer recurrence. Dutasteride is generally well tolerated and easy to take. The study will also assess its safety in women.
The goal of this study is to determine whether dutasteride can provide a simple and effective way to prevent recurrences of low-grade non-muscle-invasive bladder cancer.

Start Date23 Mar 2026

Sponsor / Collaborator

CHU de Quebec Universite Laval

NCT07417449

/ Not yet recruitingNot ApplicableIIT

The Impact of Long-Term Dutasteride Use on Surgical Outcomes and Perioperative Parameters in Patients Undergoing Holmium Laser Enucleation of the Prostate (HoLEP)

This study aims to investigate the effects of long-term dutasteride use (a 5-alpha reductase inhibitor) on surgical outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP) for benign prostatic hyperplasia (BPH).
While some studies suggest that short-term use of these medications can reduce bleeding during surgery, there is limited data on the impact of chronic, long-term use (at least 6 months) specifically during the HoLEP procedure.
The researchers will retrospectively analyze patient records to compare two groups: those who used dutasteride for 6 months or longer before surgery, and those who did not use any 5-alpha reductase inhibitors. The primary focus is to determine whether long-term dutasteride treatment leads to a significant difference in surgical bleeding (measured by hemoglobin drop), operation time, and the efficiency of removing prostate tissue (morcellation). The findings will help surgeons better understand how preoperative medication history influences the technical aspects of HoLEP surgery.

Start Date20 Mar 2026

Sponsor / Collaborator

Ankara Bilkent City Hospital

100 Clinical Results associated with Dutasteride

100 Translational Medicine associated with Dutasteride

100 Patents (Medical) associated with Dutasteride

1,201

Literatures (Medical) associated with Dutasteride

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System

Article

Author: Williams, Greg ; Bamimore, Mary A. ; Gupta, Aditya K. ; Talukder, Mesbah

BACKGROUND:

Oral finasteride 1 milligram (1 mg) daily-which is a 5-alpha reductase inhibitor (5-ARI) approved by the Food and Drug Administration (FDA) for androgenetic alopecia-is linked to sexual adverse events (AEs). However, it remains unclear whether this link is causal or merely correlational.

METHODS:

In FAERS, AEs are described by preferred terms (pts) of the Medical Dictionary for Regulatory Activities system; we investigated 8 AEs, including erectile dysfunction (pt = 10,061,461). We determined if signals could be detected with finasteride 1 mg-and 0.5 mg of dutasteride (a more potent 5-ARI)-in FAERS, for sexual AEs related to the post-finasteride syndrome (PFS): for the two, we identified the yearly number of cases (i.e. reports with sexual AEs) from 2006 to 2024. For each AE, we conducted a disproportionality analysis where reporting odds ratios (RORs) were estimated-along with p-values and 95% confidence intervals (CIs).

RESULTS:

There were more reports with finasteride 1 mg than with dutasteride 0.5 mg; for both, more reporting was observed as of 2012, the year the PFS foundation formally propagated PFS awareness.

CONCLUSIONS:

Our findings support that the disproportionately higher reporting of sexual AEs with finasteride 1 mg than with dutasteride 0.5 mg-even more so after 2012-could be attributed to the nocebo effect.

01 Mar 2026·BJU INTERNATIONAL

The role of 5‐alpha reductase inhibitors in transurethral resection of the prostate: a meta‐analysis of randomised controlled trials

Review

Author: Dowling, Gavin P. ; Daly, Gordon R. ; Hehir, Cian M. ; Calpin, Gavin G. ; Davis, Niall F. ; Cullivan, Orla

Objective:

To critically evaluate the existing evidence base surrounding the efficacy of preoperative 5‐alpha reductase inhibitor (5ARI) administration in the reduction of perioperative complication rates in transurethral resection of prostate (TURP).

Methods:

In April 2025, a systematic search of on‐line databases was conducted to identify randomised controlled trials (RCTs) that compared surgical outcomes and complication rates in patients undergoing TURP for benign prostatic hyperplasia (BPH) who were treated preoperatively with 5ARI (finasteride or dutasteride) as compared to placebo/none. The efficacy of preoperative finasteride was evaluated through outcomes related to blood loss, rate of blood transfusion, and operative time. The physiological mechanism of 5ARI treatment was evaluated through microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression of the resected specimen.

Results:

A total of 30 RCTs met the inclusion criteria for this meta‐analysis in which a total of 2974 patients underwent TURP for BPH (1464 5ARI: 1410 Control). Intraoperative blood loss was significantly lower among 5ARI‐treated patients ( Z = 6.37, mean difference [MD] = −82.58 mL, 95% confidence interval [CI] −107.98 to −57.18; P < 0.001), which was reflected in a significantly lesser haemoglobin drop on the first postoperative day ( Z = 6.84, MD = −0.90 g/dL, 95% CI−1.16 to −0.64; P < 0.001). The MVD was significantly lower in resected specimens from 5ARI‐treated patients (MD = −6.18 vessels/mm 3 , P < 0.001), whilst expressing significantly less VEGF (MD = −3.25, P < 0.001). Patients treated with 5ARI required blood transfusion less frequently than controls (odds ratio 0.31, P < 0.001). The use of 5ARI was associated with shorter operative time (MD = −3.47 min, P = 0.02) and lower volume of irrigation agents (MD = –2.07 L, P < 0.001).

Conclusion:

Preoperative administration of 5ARIs significantly reduces intraoperative blood loss and risk of requiring blood transfusion in patients undergoing TURP for BPH. Even short durations (2 weeks) of 5ARI therapy can significantly reduce prostate vascularity.

01 Jan 2026·INTERNATIONAL JOURNAL OF DERMATOLOGY

Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System

Article

Author: Keene, Sharon A. ; Bamimore, Mary A. ; Gupta, Aditya K. ; Talukder, Mesbah

ABSTRACT:

Background:

The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation. These AEs are controversial and often lack assessment of contributing risk factors. We analyzed FDA Adverse Event Reporting System (FAERS) data to explore finasteride's administration route and PFS‐like AEs.

Methods:

Using the information component (IC) method for disproportionality analyses, we assessed signals for 13 PFS‐related AEs with topical and oral finasteride and dutasteride across two periods: 2006–2011 (pre‐PFS reporting) and 2019–2024 (post‐PFS reporting). These periods reflect times before and after formal PFS reporting in 2012. Eight analyses per AE were conducted based on agent, route, and era.

Results:

Fewer signals for PFS‐like AEs were detected with topical finasteride compared to oral finasteride in both eras. No signals were found for topical dutasteride, possibly because its use is very limited. Many reported AEs, such as erectile dysfunction and depression, may be influenced by age, stress, or comorbidities.

Conclusions:

Signals for PFS‐like AEs were detected with topical finasteride, but were less frequent than with oral finasteride. The high prevalence of these AEs in the general population and the influence of confounding factors, such as psychological stress or nocebo effects, combined with the lack of genotyping, hormonal assessments, or family history data in most reports, suggest caution in attributing causality to finasteride. Topical finasteride may pose a lower risk, but robust evidence is needed to clarify its safety profile.

News (Medical) associated with Dutasteride

27 Jan 2026

·www.einpresswire.com

Dutasteride Mesotherapy Now Available for Hair Loss Treatment in Kitchener-Waterloo at True North Metabolic

Physician-led scalp micro-injections delivering targeted dutasteride for androgenic alopecia in men and post-menopausal women in Kitchener-Waterloo. KITCHENER, ONTARIO, CANADA, January 27, 2026 / EINPresswire.com / -- True North Metabolic, a physician-led clinic serving Kitchener-Waterloo, has introduced Dutasteride Mesotherapy in Kitchener-Waterloo as a modern, evidence-informed option for patients seeking treatment for patterned hair loss. This service is designed for men with male pattern baldness (androgenic alopecia) and for post-menopausal women experiencing androgen-driven thinning. Hair loss in androgenic alopecia is driven in part by dihydrotestosterone (DHT) acting at the level of the hair follicle. Dutasteride is a medication known to reduce DHT, and mesotherapy is a technique that delivers small amounts into the scalp through micro-injections. The goal of this Hair Loss Treatment approach is to target the scalp—where the follicles are—while aiming to minimize unnecessary systemic exposure. Who this may be for Dutasteride Mesotherapy in Kitchener-Waterloo at True North Metabolic is offered to: Men with male pattern baldness (androgenic alopecia) who want an evidence-informed option focused on scalp-level Hair Loss Treatment option Post-menopausal women with patterned thinning where androgen activity may play a role Patients who want a structured medical assessment and a supervised treatment plan tailored to hair-loss pattern, timeline, and goals What a typical visit looks like Patients begin with a physician assessment to confirm the likely cause of hair loss and to review medical history, current medications, and treatment goals. The procedure involves intradermal micro-injections to targeted scalp areas. Hair Loss Treatment intervals are individualized, and follow-up plans typically focus on consistent tracking and realistic expectations, since hair growth cycles require time. Combining therapies for better results For some patients, Dutasteride Mesotherapy in Kitchener-Waterloo can be part of a broader plan that may include topical therapies, oral medication options when appropriate, and supportive hair-health measures. True North Metabolic’s focus is to provide a medically guided pathway rather than a one-size-fits-all approach. Physician-led care in Kitchener-Waterloo As a physician-led clinic, True North Metabolic emphasizes proper candidate selection, clear counseling, and a structured plan. Patients are provided with information on expected timelines, how response is monitored, and what additional treatment options may be considered based on progress. Patients interested in Dutasteride Mesotherapy for patterned Hair Loss Treatment can request an appointment at True North Metabolic in Kitchener-Waterloo. In addition to offering Dutasteride Mesotherapy in Kitchener-Waterloo as an option for Hair Loss Treatment ; True North Metabolic also now offers Body Composition Testing with medical-grade accuracy with our Inbody 770 machine. Other unique services being offered include: Body Composition Testing : https://www.truenorthmetabolic.com/body-composition-analysis-kitchener-waterloo Men's Health Services : https://www.truenorthmetabolic.com/kitchener-waterloo-men-s-health About True North Metabolic True North Metabolic is a physician-led clinic in Kitchener-Waterloo focused on metabolic health, men’s health, and evidence-informed wellness services. The clinic provides medical assessments and structured treatment plans with an emphasis on safety, clarity, and measurable outcomes. You can learn more at https://www.truenorthmetabolic.com Mike Souza KWC +1 614-974-7684 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

01 Nov 2025

·www.einpresswire.com

True North Metabolic Expands Testosterone Replacement Therapy in Kitchener-Waterloo

Physician-led TRT program adds structured assessment, monitoring, and treatment options for men across Kitchener-Waterloo, Cambridge, and Guelph, Ontario. KITCHENER, ONTARIO, CANADA, November 1, 2025 / EINPresswire.com / -- True North Metabolic announced the expansion of its physician-led Testosterone Replacement Therapy (TRT) service for residents of Kitchener-Waterloo, Cambridge, and Guelph, Ontario, delivering a clear, evidence-based pathway from assessment to ongoing care. The program centralizes men’s health evaluation, lab timing guidance, therapy selection, and structured monitoring to help patients achieve symptom relief while maintaining safety. Service information is available at: • Men’s Health overview: https://www.truenorthmetabolic.com/kitchener-waterloo-men-s-health • TRT service page: https://www.truenorthmetabolic.com/kitchener-testosterone-replacement-therapy A Physician-Led, Mechanism-Focused Approach True North Metabolic’s care model emphasizes the mechanisms behind hypogonadism and the practical realities of daily treatment. Patients begin with a structured intake that documents symptoms (libido, energy, sleep, mood, body composition), medical history, and medications, followed by targeted morning labs and confirmatory testing when indicated. The clinic’s protocol aligns therapy with physiology—beginning only when diagnostic criteria are met—and pairs treatment with scheduled follow-ups to evaluate benefits, side effects, and adherence. Why TRT, and For Whom TRT may be appropriate for men with persistent symptoms and repeatedly low morning testosterone levels. The clinic counsels on realistic goals: improved sexual function, energy, strength, and sleep quality, while monitoring for potential risks such as erythrocytosis, blood pressure or lipid changes, fertility suppression, acne, edema, or sleep apnea exacerbation. Patients in Kitchener-Waterloo, Cambridge, Ontario and Guelph, Ontario receive individualized care plans that consider work schedules, training demands, and family-building timelines. Therapy Options Tailored to Daily Life The clinic offers multiple TRT routes and helps men choose the option that matches their routine, personal preferences and monitoring preferences: Topical gel (once daily): convenient and steady levels; requires transfer precautions and consistent application. Intranasal gel (three times daily): rapid on/off kinetics with low transfer risk; ideal for flexible dose titration. Injections: Shorter-acting (cypionate/enanthate): weekly or twice-weekly dosing, intramuscular or subcutaneous; cost-effective with predictable levels. Long-acting undecanoate (IM): infrequent clinic dosing with stable levels and observation period. Oral testosterone undecanoate (capsules): limited availability; considered case-by-case with counseling on cost and expectations. The TRT program integrates lifestyle modifications so patients see durable improvements beyond the prescription. Safety, Monitoring, and Follow-Up True North Metabolic’s protocol schedules labs at predictable intervals: early rechecks and then at regular intervals. Monitoring includes hematocrit/hemoglobin, testosterone levels timed to route, PSA where indicated, lipids, and blood pressure. The clinic also screens for obstructive sleep apnea and explores fertility-preserving alternatives when family planning is a priority. Adverse effects are managed through dose adjustment, route changes, or coordinated specialty referral when needed. Care That Extends Beyond Testosterone Men often present with overlapping concerns—weight gain, metabolic risk, and hair loss—that affect confidence and long-term health. True North Metabolic connects TRT care to additional services so patients have a single, coherent plan: Weight Loss Clinic (Kitchener-Waterloo) : evidence-based nutrition programs and medication options when appropriate, with an emphasis on cardiometabolic risk and lean-mass preservation. Learn more: https://www.truenorthmetabolic.com/kitchener-waterloo-weight-loss-clinic Hair Loss Care: mechanism-focused plans for androgenic alopecia, including counseling on finasteride or dutasteride and topical minoxidil, with realistic timelines for stabilization and regrowth. Details: https://www.truenorthmetabolic.com/kitchener-waterloo-hair-loss By aligning men’s health, weight management, and hair loss care, the clinic helps patients in Kitchener-Waterloo, Cambridge, Ontario and Guelph, Ontario move toward performance, aesthetics, and longevity goals in a single, coordinated pathway. About Clinical Leadership The testosterone replacement therapy (TRT) service is overseen by Dr. Khashayar Farzam, whose practice focuses on metabolic health for all adults and pediatrics and in addition; men’s health services which focuses on TRT. Dr. Farzam’s guidance informs the clinic’s structured intake, diagnostic workflows, and longitudinal monitoring protocols. More information about clinical leadership is available at: https://www.truenorthmetabolic.com/our-doctors Access, Service Area, and Booking True North Metabolic serves patients across Kitchener-Waterloo, Cambridge, Ontario and Guelph,Ontario; with appointment times designed for busy professionals. The clinic provides clear next steps after each visit, including lab requisitions, follow-up dates, and route-specific instructions to help patients stay on track. Patients can self-refer for a TRT assessment or seek a referral from their primary care provider. What Patients Can Expect at a First Visit History and goals: a focused discussion on symptoms, training, sleep, and health priorities. Diagnostic testing: morning testosterone measurements on two separate days, plus targeted labs where indicated. Plan selection: route of administration (gel, intranasal, injection, or oral TU if appropriate) with education on dosing, application technique, and monitoring. Follow-up roadmap: scheduled rechecks, symptom scores, and coaching support for sustainable changes in energy, body composition, and performance. Community Focus: Kitchener-Waterloo, Cambridge, Ontario and Guelph, Ontario The clinic’s expansion reflects local demand for structured, physician-led men’s health services. By centralizing evaluation and care under one roof—and tying TRT to weight and hair loss services—True North Metabolic aims to set a regional standard that balances outcomes with safety and education. The model highlights early identification of contraindications, realistic counseling on timelines, and a practical approach to adherence. Call to Action Residents of Kitchener-Waterloo, Cambridge, Ontario and Guelph, Ontario seeking evidence-based TRT can review service details and request an assessment at: • Men’s Health overview: https://www.truenorthmetabolic.com/kitchener-waterloo-men-s-health • TRT program: https://www.truenorthmetabolic.com/kitchener-testosterone-replacement-therapy For related needs, explore: • Weight Loss Clinic: https://www.truenorthmetabolic.com/kitchener-waterloo-weight-loss-clinic • Hair Loss Care: https://www.truenorthmetabolic.com/kitchener-waterloo-hair-loss Media Contact True North Metabolic Kitchener, Ontario Web: https://www.truenorthmetabolic.com/kitchener-testosterone-replacement-therapy Phone: (226) 686-0119 Mike Souza KWC info@truenorthmetabolic.com Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

27 Oct 2025

·www.einpresswire.com

True North Metabolic Expands Evidence-Based Hair Loss Treatment in Kitchener-Waterloo-Cambridge, Ontario

Physician-led program focuses on male pattern baldness mechanisms and proven therapies—finasteride, dutasteride, and minoxidil—in Kitchener-Waterloo. KITCHENER, ONTARIO, CANADA, October 27, 2025 / EINPresswire.com / -- True North Metabolic today announced the expansion of its physician-led hair loss treatment in Kitchener-Waterloo, offering a comprehensive, mechanism-driven program for men experiencing androgenic alopecia (male pattern baldness). The clinic’s protocol integrates diagnostic assessment with evidence-based therapies, including finasteride, dutasteride, and minoxidil, supported by ongoing follow-up and education. Full details are available at: https://www.truenorthmetabolic.com/kitchener-waterloo-hair-loss . Male pattern baldness is driven by the interaction between dihydrotestosterone (DHT) and genetically susceptible follicles, which shortens the hair growth phase and progressively miniaturizes follicles on the hairline and crown. True North Metabolic’s program is built around this biology. The care pathway begins with a structured history, pattern mapping, and targeted lab review when indicated, followed by a personalized plan that addresses both upstream hormone signaling and downstream follicle support. Program Highlights Mechanism-Focused Care: The clinic prioritizes the core drivers of androgenic alopecia—DHT, androgen receptor sensitivity, and follicular miniaturization—so each patient’s plan aims to stabilize loss before rebuilding density. There is also major emphasis on ruling out other causes of hair loss before concluding that the diagnosis is androgenic alopecia aka male pattern baldness. Evidence-Based Medications: Finasteride (selective type 2 5-alpha reductase inhibitor) to reduce scalp and serum DHT and slow miniaturization. Dutasteride (type 1 and type 2 5-alpha reductase inhibitor) as an option when additional DHT suppression is appropriate. Minoxidil (topical) to lengthen anagen, increase follicle size, and support regrowth; often paired with a DHT-lowering agent for synergy. Structured Follow-Up: Clear timelines for reassessment (typically 3, 6, and 12 months) to track density, shedding, and treatment adherence, with dose adjustments or adjuncts as needed. Lab tests: Ensuring no secondary causes such as hypothyroidism or iron deficiency Ruling out other causes of hair loss: Other causes can include telogen effluvium and alopecia areata Lifestyle and Scalp Health: Counseling on scalp care, medication routines, and factors that can magnify telogen shedding (e.g., severe calorie deficits, poor sleep), while emphasizing that androgenic alopecia is a biologically programmed process best managed early. Why This Matters in Kitchener-Waterloo Search interest for hair loss treatment in Kitchener-Waterloo continues to grow as more men seek reliable, medical guidance rather than one-size-fits-all products. True North Metabolic’s program is designed for clarity and consistency: patients know the mechanism being targeted, which interventions are expected to stabilize versus regrow, and when to anticipate visible changes. The clinic’s location and scheduling accommodate professionals across Kitchener, Waterloo, Cambridge, and surrounding communities. Review of Clinical Leadership The program is overseen by Dr. Khashayar Farzam, a physician with a strong focus on metabolic and men’s health. The clinic’s approach reflects a medical model: assess, plan, treat, and monitor—precisely aligned with the pathophysiology of androgenic alopecia. Patients can expect clear counseling on benefits, timelines, and maintenance, particularly around long-term strategies with finasteride, dutasteride, and minoxidil in Kitchener-Waterloo. Patient Journey and Expectations Assessment: Pattern mapping, history (onset, family history, shedding), medication review, and targeted labs when indicated. Plan: Selection of DHT-targeting therapy (finasteride or dutasteride) plus topical minoxidil, with education on application, adherence, and expected timelines. Select cases may require oral minoxidil after extensive risk and benefit discussion. Early Phase (0–8 weeks): Possible transient shedding as older telogen hairs cycle out; adherence and technique are reinforced. Consolidation (3–6 months): Stabilization is the first milestone; early thickening and improved coverage may be observed in many cases. Maintenance (6–12+ months): Ongoing improvements depend on consistent use and biology; stopping treatment typically allows the original pattern to resume. Plans are adjusted or escalated if goals are not met. Quality, Safety, and Monitoring True North Metabolic emphasizes informed consent, evidence-based dosing, and follow-up to evaluate response and tolerability. Patients receive guidance on what is typical versus what warrants reassessment, along with practical strategies for daily routines. The clinic also coordinates with family physicians when requested and provides treatment summaries upon consent. Access and Scheduling Residents seeking kitchener hair loss or waterloo hair loss solutions can book an assessment online or by phone. The clinic offers flexible visit formats and clear next steps after each appointment. The dedicated page—** https://www.truenorthmetabolic.com/kitchener-waterloo-hair-loss**—outlines the program structure, medication options, and frequently asked questions to help prospective patients prepare for hair loss treatment in Kitchener-Waterloo. About True North Metabolic True North Metabolic is a Kitchener-based clinic focused on metabolic health, men’s health, and evidence-based interventions for conditions that impact quality of life and performance. The clinic’s hair loss service integrates medical expertise with practical, stepwise care to help patients stabilize loss and pursue durable coverage. Call to Action For more information about hair loss treatment in Kitchener-Waterloo—including finasteride, dutasteride, and minoxidil in Kitchener-Waterloo—visit https://www.truenorthmetabolic.com/kitchener-waterloo-hair-loss or email the clinic at info@truenorthmetabolic.com Media Contact True North Metabolic Kitchener, Ontario Phone: (226) 686-0119 Web: https://www.truenorthmetabolic.com/kitchener-waterloo-hair-loss Mike Souza KWC email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Dutasteride

External Link

KEGG	Wiki	ATC	Drug Bank
D03820	Dutasteride	G04CB02	DB01126

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Androgenetic Alopecia	Japan	GSK Plc	28 Sep 2015
Prostatic Hyperplasia	United States	Waylis Therapeutics LLC	20 Nov 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma of prostate	Phase 3	Canada	GSK Plc	01 Mar 2007
Localized Prostate Carcinoma	Phase 3	United States	GSK Plc	01 Nov 2005
Prostatic Cancer	Phase 3	United States	GSK Plc	01 Mar 2003
Prostatic Cancer	Phase 3	Japan	GSK Plc	01 Mar 2003
Prostatic Cancer	Phase 3	Argentina	GSK Plc	01 Mar 2003
Prostatic Cancer	Phase 3	Australia	GSK Plc	01 Mar 2003
Prostatic Cancer	Phase 3	Austria	GSK Plc	01 Mar 2003
Prostatic Cancer	Phase 3	Belarus	GSK Plc	01 Mar 2003
Prostatic Cancer	Phase 3	Belgium	GSK Plc	01 Mar 2003
Prostatic Cancer	Phase 3	Brazil	GSK Plc	01 Mar 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO_GU2026	Not Applicable	Renal Cell Carcinoma	185	5-ARIs (finasteride/dutasteride) exposed	jgpmckwdiz(oanrhmemlu) = yvxegitvpk drshencstv (upvgyrkvyh ) View more	Positive	26 Feb 2026
				Non-5-ARIs exposed	jgpmckwdiz(oanrhmemlu) = devezslant drshencstv (upvgyrkvyh ) View more
NCT04098302 (CTgov)	Phase 2/3	Alcohol Use Disorder	180	Dutasteride Capsules (Dutasteride)	mzplnemxsz(dmmtzghxln) = ymgettxrqo smdvpqltsq (mzhojyctdy, 0.33) View more	-	09 May 2025
				Placebo Capsules (Placebo Capsule)	mzplnemxsz(dmmtzghxln) = baukzcpyzz smdvpqltsq (mzhojyctdy, 0.28) View more
NCT02213107 (phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI), CTgov)	Phase 2	Recurrent Prostate Carcinoma \| Prostatic Cancer \| Localized Prostate Carcinoma ... View more	43	finasteride+Enzalutamide+Dutasteride	sudffegypi = jfaddedndx urxawnuuzh (vtyekurgwd, fsbrsoztjf - ycapcdmbsx) View more	-	13 Nov 2024
NCT02213107 (ASCO2024) Manual	Phase 2	Castration-sensitive prostate cancer	43	Enzalutamide 16Dutasteride+ DFinasteride0.5mg daily	pgvtkwepnk(hrnpgryiqx) = ysksftsyft latqapxcck (vkauxliavm ) View more	Positive	24 May 2024
NCT01758523 (Pubmed \| J Clin Psychopharmacol)	Phase 4	Alcoholism	142	Dutasteride 1 mg	ijtnwhqmwh(qcwbndfnnf) = Adverse events more common in the dutasteride group were reduced libido sfjejpnyec (tkmwdnotpc ) View more	Positive	01 May 2024
				Placebo
NCT00668642 (CTgov)	Phase 2	Advanced Prostate Carcinoma	20	Dutasteride (A: Dutasteride During First Off-Cycle)	eqhmjffmpu(zdtiieyqcy) = jeyvuiqbff lpkkclelum (unbrdxjsqc, 0.5) View more	-	22 Aug 2023
				Placebo (B: Placebo During First Off-Cycle)	eqhmjffmpu(zdtiieyqcy) = srkpugqshr lpkkclelum (unbrdxjsqc, 0.45) View more
NCT01342367 (Prospective Trial Of Oral-Only Hormonal Therapy With Radiation, CTgov)	Not Applicable	Non-metastatic prostate cancer	74	bicalutamide+leuprolide+goserelin (SOC Cohort)	iizxkkkwej(ajvnqrzlgv) = titixnebdn rjsmhboxyc (hzwmhvgzyb, 0.04) View more	-	28 Oct 2021
				finasteride+dutasteride+bicalutamide (Oral ADT Group)	iizxkkkwej(ajvnqrzlgv) = uuaqokstfp rjsmhboxyc (hzwmhvgzyb, 0.04) View more
NCT02213107 (ESMO2020)	Phase 2	Prostatic Cancer	43	Enzalutamide 160mg daily + Dutasteride 0.5mg daily	pkzsjtjmrk(gumprluvul) = the most common any grade AE was fatigue (65%) yflbjnqiuj (vtvqcrnhnk ) View more	Positive	17 Sep 2020
				Enzalutamide 160mg daily + Finasteride 5mg daily
NCT02213107 (ASCO2019)	Phase 2	Prostatic Cancer	43	Enzalutamide 160 mg/day + Dutasteride 0.5 mg/day	rxxmyxzzmn(xrasidfsrj) = kchxsnfugi mlspjsuuft (vbhgbwvrnm ) View more	Positive	26 May 2019
NCT01758523 (CTgov)	Phase 4	Alcoholism	189	Dutasteride (Dutasteride)	bszdpzmkbs(verfjntlqe) = tjxlnozgow wieyovheee (iysjbomyru, 0.33) View more	-	26 Apr 2019
				sugar pill (Sugar Pill)	bszdpzmkbs(verfjntlqe) = anejvhqnkk wieyovheee (iysjbomyru, 0.34) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis